GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Repligen Corporation
Repligen is a key supplier of bioprocessing materials (such as filtration systems) for the production of biological drugs. Its stock price reflects the growth of the biopharmaceutical industry. The chart shows how the company benefits from increased vaccine and antibody production.
Share prices of companies in the market segment - Dna
Repligen operates in the bioprocessing segment, supplying critical products for the production of biopharmaceuticals. We classify it as part of the DNA technology sector, as its products are used in gene therapy. The chart below shows the dynamics of this rapidly growing segment.
Broad Market Index - GURU.Markets
Repligen is a leading provider of bioprocessing technologies and materials used in the production of biological drugs, such as antibodies and vaccines. Its industry weight earns it a spot in the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
RGEN - Daily change in the company's share price Repligen Corporation
Change_Co for Repligen Corporation (RGEN), a supplier of bioprocessing materials to drugmakers, reflects sensitivity to the biotech sector's growth rate and large contracts. RGEN's volatility is a direct measure of market expectations for high-tech medical solutions. Our system uses this metric for formulaic analysis of innovative but volatile biotech assets.
Daily change in the price of a set of shares in a market segment - Dna
Repligen Corporation is a supplier of bioprocessing technologies to the pharmaceutical industry. This chart shows the sector's average daily volatility. Comparison with RGEN, a key supplier for biopharmaceutical production, helps assess its stability.
Daily change in the price of a broad market stock, index - GURU.Markets
Repligen is a leading supplier of products used in the production of biological drugs. Its business is a barometer of the health of the entire biotech industry. The chart below shows the volatility in this sector, helping to assess Repligen's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Repligen Corporation
Repligen is a key supplier of bioprocessing products used in the production of biological drugs. Its year-over-year growth serves as a barometer of R&D investment in the biotech industry. The chart below provides a snapshot of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Dna
Repligen Corporation is a leading provider of bioprocessing technologies used in the production of biological drugs. Its products help improve efficiency and reduce production costs. The chart shows how its key role in this rapidly growing niche is driving its accelerated growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Repligen supplies critical components for the production of biopharmaceuticals. It's a gold mine in the biotech world. Demand for its products is stable and unaffected by economic cycles, as drug development continues unabated. The company's stock price has demonstrated consistent growth, typical of defensive sectors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Repligen Corporation
Repligen, a supplier of consumables and equipment for biopharmaceutical manufacturing. The monthly fluctuations on the chart reflect investments in R&D and manufacturing by pharmaceutical companies that use its products (for example, for filtration) at all stages of drug development.
Monthly dynamics of market capitalization of the market segment - Dna
This chart reflects the dynamics of the biotech sector. For Repligen, a key supplier to the biopharmaceutical industry, this is the backdrop. Its movements show how demand for its products for the production of biologics (such as monoclonal antibodies) is growing along with the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Repligen is a key supplier of consumables and equipment for the production of biopharmaceuticals, such as monoclonal antibodies and gene therapy. The chart below shows general market trends. How much does Repligen, as a "shovel supplier" to the biotech industry, depend on these, and how much does it depend on the success of the industry itself?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Repligen Corporation
Repligen, a supplier of materials for biopharmaceutical production, is feeling the pulse of the biotech industry. Its weekly stock price reflects investment in the development of new drugs, particularly monoclonal antibodies and gene therapy.
Weekly dynamics of market capitalization of the market segment - Dna
As a supplier of bioprocessing materials, Repligen depends on the overall health and growth of the entire biopharmaceutical industry. The growth of the monoclonal antibody and gene therapy markets is a common thread that is lifting all suppliers. The chart below shows how RGEN's performance aligns with the overall growth of biotech R&D.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a key supplier to the pharmaceutical industry, Repligen may demonstrate defensive qualities. Demand for its bioprocessing materials is weakly dependent on economic conditions, which may make its shares more stable than the overall market. The chart will help assess whether RGEN truly is a safe haven during periods of general market turbulence.
Market capitalization of the company, segment and market as a whole
RGEN - Market capitalization of the company Repligen Corporation
Repligen's stock price reflects the growth of the biopharmaceutical industry. The company supplies critical materials and technologies (such as filtration systems) for the production of biological drugs such as antibodies. Its market capitalization dynamics reflect investors' valuation of this "infrastructure" business, which is growing alongside the industry.
RGEN - Share of the company's market capitalization Repligen Corporation within the market segment - Dna
Repligen is a key supplier of bioprocessing technologies used to produce biological drugs. Its market share reflects its dominance in the filtration and chromatography systems niche. The chart below shows how its share has grown alongside the rapid development of the biopharmaceutical market.
Market capitalization of the market segment - Dna
Repligen supplies bioprocessing technologies used to produce biological drugs such as antibodies and vaccines. The chart below shows the market capitalization of this critically important pharmaceutical sector. Its growth reflects the boom in biopharma and gene therapy.
Market capitalization of all companies included in a broad market index - GURU.Markets
Repligen is a leading provider of bioprocessing technologies used in the production of biological drugs (biopharmaceuticals). The company's market capitalization reflects the explosive growth of this pharmaceutical sector. Its market share represents the weight of the "shovels and picks" in the biotech gold rush—that is, the technologies without which mass production of modern medicines is impossible.
Book value capitalization of the company, segment and market as a whole
RGEN - Book value capitalization of the company Repligen Corporation
Repligen's core business is high-tech biopharmaceutical manufacturing. The company's book value reflects its facilities producing filtration and chromatography systems, which are essential for purifying biological drugs such as antibodies and vaccines. The chart below shows how the company expanded its production capacity, becoming a key supplier to the industry.
RGEN - Share of the company's book capitalization Repligen Corporation within the market segment - Dna
Repligen manufactures bioreactors and systems for the biopharmaceutical industry at its own facilities. These production facilities are its key tangible assets. The S_BCap_Seg graph shows the company's control over the biotechnology equipment manufacturing infrastructure.
Market segment balance sheet capitalization - Dna
The chart shows the overall book value of the biotechnology sector. Against this backdrop, Repligen, as a supplier of "consumables" for biopharmaceuticals, is capital-intensive. The production of filtration systems and proteins requires the ownership of modern, certified factories.
Book value of all companies included in the broad market index - GURU.Markets
Repligen produces and sells bioprocessing materials used to manufacture biological drugs. The company's assets include specialized factories and laboratories. Compared to the entire pharmaceutical industry, which can be visualized by this graph, Repligen creates "tools and consumables" for its most advanced "workshops."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Repligen Corporation
Repligen's balance sheet is the value of its factories producing consumables for biopharmaceuticals. Its market capitalization is a measure of its critical role as a "shovel supplier" during the biotech gold rush. The MvsBCap_Co chart shows a huge premium for its participation in the growth of the entire pharmaceutical industry.
Market to book capitalization ratio in a market segment - Dna
Repligen supplies bioprocessing technologies for the production of biological drugs. Its products are critical to the pharmaceutical industry. The chart shows the market premium it places on its innovative solutions and strong position in the niche. This reflects its confidence in the growth of the biopharmaceutical market.
Market to book capitalization ratio for the market as a whole
Repligen Corporation is a leading provider of bioprocessing technologies and materials used in the production of biological drugs. The company's value lies in its innovative products, patents, and strong relationships with pharmaceutical companies. This chart illustrates why companies providing critical biotech solutions can command a premium.
Debts of the company, segment and market as a whole
RGEN - Company debts Repligen Corporation
Repligen, a provider of bioprocessing technologies for drug production, uses debt for innovation and acquisitions. This chart illustrates how the company raises capital to acquire companies with unique filtration and chromatography technologies. For them, debt is a way to strengthen their position as a key supplier to the biopharmaceutical industry.
Market segment debts - Dna
Repligen supplies bioprocessing technologies used in the production of biological drugs, such as monoclonal antibodies. The rapid growth of the biotech industry is driving demand for the company's products. This chart shows how Repligen is funding its expansion and innovation to keep pace with the needs of its pharmaceutical clients.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Repligen Corporation
Repligen supplies bioprocessing technologies necessary for the production of biological drugs. This chart shows how the company is financing its rapid growth amid the biotech revolution. Its debt level may reflect an acquisition strategy to expand its product portfolio and strengthen its position as a key supplier to the pharmaceutical industry.
Market segment debt to market segment book capitalization - Dna
Repligen Corporation supplies materials and technologies for biopharmaceutical manufacturing, such as vaccines and gene therapy. This chart reflects debt trends in the life sciences sector. It helps assess how Repligen is financing its rapid growth, driven by the biotech boom, and how aggressive its acquisition strategy is in this market.
Debt to book value of all companies in the market
Repligen, a supplier to the biopharmaceutical industry, relies on innovation in biotech. The chart reflects the market's overall debt burden. It allows one to assess the extent to which the biotech boom, which is driving demand for Repligen's products, allows the company to pursue investment and financial policies independent of macroeconomic cycles.
P/E of the company, segment and market as a whole
P/E - Repligen Corporation
This chart shows the valuation of Repligen, a supplier of consumables for biopharmaceutical manufacturing. The high P/E is justified by the company's key role in the production of biologics, such as monoclonal antibodies. A decline could be due to reduced R&D budgets at pharmaceutical companies or industry consolidation.
P/E of the market segment - Dna
This industry metric represents the average P/E for life sciences providers. For Repligen, with its focus on bioprocessing, it's an important benchmark. Its significantly higher P/E than average reflects the premium it commands for its dominant position in the fast-growing biologics niche.
P/E of the market as a whole
Repligen Corporation supplies materials and technologies used in the production of biological drugs (biopharmaceuticals). The company is a key supplier to the growing biotechnology industry. This chart of overall market valuations helps us understand whether Repligen's price reflects a premium for its strategic role in producing the drugs of the future, making it less susceptible to overall market cycles.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Repligen Corporation
Repligen Corporation supplies bioprocessing materials and equipment necessary for the production of biological drugs, such as monoclonal antibodies and gene therapies. The company's future growth depends on the growth of the biopharmaceutical market. This chart shows how investors view Repligen's critical role in the production of modern medicines and its technological leadership.
%20P%2FE%20Repligen%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Repligen-Corporation&v=1772513687136 "Chart of the company's future (projected) P/E Repligen Corporation")
Future (projected) P/E of the market segment - Dna
Repligen Corporation is a leading provider of bioprocessing technologies used in the production of biological drugs (such as monoclonal antibodies). The company's products help create medicines. This chart reflects expectations for the biotech sector, allowing us to assess how highly the market values Repligen's "infrastructure" role in the growing pharmaceutical industry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513687139 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Repligen supplies bioprocessing technologies necessary for the production of biological drugs, such as monoclonal antibodies and gene therapies. Their growth is directly linked to the success of the biotech industry. This graph of overall expectations demonstrates investor appetite for innovation. Market optimism is driving an influx of funding into biotech, leading to increased drug production and demand for Repligen's products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513687156 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Repligen Corporation
Repligen Corporation supplies bioprocessing materials and equipment used in the production of biological drugs (biopharmaceuticals). The steady growth in this graph is driven by the rapid development of biotechnology. The company's profits are growing along with the increased production of monoclonal antibodies and gene therapy, as its products are critical to these processes.
Profit of companies in the market segment - Dna
Repligen Corporation supplies materials and technologies for the production of biological drugs (biopharmaceuticals). The company's profitability is growing alongside the monoclonal antibody and gene therapy markets. This chart shows how advances in biotechnology are creating stable and growing demand for consumables, ensuring high profitability for suppliers in this critical sector.
Overall market profit
Repligen Corporation supplies innovative materials and technologies for the production of biological drugs, such as monoclonal antibodies and gene therapies. The company is a key supplier to the biopharmaceutical industry. Demand for its products grows alongside the biopharmaceutical market, making its business resilient to general economic cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Repligen Corporation
Repligen Corporation supplies bioprocessing products used in the production of biological drugs, such as monoclonal antibodies and gene therapies. The company's profit forecast depends on the growth of the biopharmaceutical market. This chart shows analyst expectations for increased production of complex drugs and Repligen's role as a key supplier.
%20profit%20of%20the%20company%20Repligen%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Repligen-Corporation&v=1772513687178 "Graph of future (projected) profit of the company Repligen Corporation")
Future (predicted) profit of companies in the market segment - Dna
Repligen develops and supplies bioprocessing technologies used in the production of biological drugs, such as monoclonal antibodies and gene therapies. The company was a "shovel supplier" during the biotech gold rush. This chart shows profitability forecasts for the sector, reflecting how aggressively the pharmaceutical industry is investing in the production of new drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513687200 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Repligen supplies consumables and equipment for the production of biological drugs. The company's growth is directly linked to the success of the biotech industry. This chart, showing overall profit expectations, reflects the investment climate. A positive outlook encourages capital inflows into biotech, leading to expanded drug production and increased demand for Repligen's products.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513687213 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Repligen Corporation
Repligen Corporation supplies critical materials and technologies used in the production of biological drugs (biopharmaceuticals). These are essentially the "shovels and picks" of the biotech revolution. Its high revenue valuation in this chart reflects investors' confidence in the long-term growth of complex drugs like monoclonal antibodies.
P/S market segment - Dna
Repligen Corporation is a bioprocessing company that develops and markets products used in the production of biological drugs, such as monoclonal antibodies and gene therapies. This chart shows the average valuation for the sector, providing insight into how highly the market values Repligen's key role in the production of modern medicines.
P/S of the market as a whole
Repligen Corporation supplies bioprocessing technologies used in the production of biological drugs, such as monoclonal antibodies and gene therapy. The company is a key supplier to the pharmaceutical industry. This chart helps assess the market's willingness to value the company's revenue for producing cutting-edge drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Repligen Corporation
Repligen Corporation supplies innovative materials and technologies used in the production of biological drugs (biopharmaceuticals). This chart shows how the market estimates the company's future revenue. It reflects expectations for growth in the global biopharmaceutical market and demand for Repligen's products, which help improve the efficiency of drug production.
%20P%2FS%20Repligen%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Repligen-Corporation&v=1772513687238 "The graph of the company's future (projected) P/S Repligen Corporation")
Future (projected) P/S of the market segment - Dna
Repligen Corporation supplies critical materials and technologies used in the production of biologics, such as monoclonal antibodies and gene therapies. This chart compares the company's estimated future sales with its industry, reflecting investor confidence in the continued growth of the biopharmaceutical industry.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513687243 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Overall revenue expectations for the economy depend on innovation in the biopharmaceutical industry. Repligen, supplying critical materials and technologies for the production of biological drugs, is a "supplier to suppliers." Demand for its products from leading pharmaceutical companies reflects the growth in the production of new drugs, which drives the entire industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513687248 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Repligen Corporation
Repligen supplies critical technologies and materials for the production of biological drugs. The company's revenue is generated by selling its products, such as filtration and chromatography systems, to biopharmaceutical companies. This chart shows how the growth of the biopharmaceutical industry, including vaccines and antibodies, directly drives Repligen's business.
Sales of companies in the market segment - Dna
Repligen Corporation is a leading provider of innovative bioprocessing technologies and materials used in the production of biological drugs, such as monoclonal antibodies and gene therapies. This chart shows total revenue in the DNA technologies sector. It reflects the growth of the biopharmaceutical industry, which requires Repligen's purification and filtration products.
Overall market sales
Repligen Corporation supplies innovative bioprocessing technologies and materials used in the production of biological drugs, such as monoclonal antibodies and gene therapies. Demand for its products depends on activity in the biopharmaceutical industry. This graph of overall economic growth indirectly reflects investment in the development and production of new drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Repligen Corporation
Repligen develops and supplies materials and technologies used in the production of biological drugs (bioprocessing). Demand for its products is directly linked to the growth of the biopharmaceutical market. The chart shows analyst revenue forecasts, reflecting their expectations for production volumes of monoclonal antibodies, vaccines, and gene therapy.
%20sales%20of%20the%20company%20Repligen%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Repligen-Corporation&v=1772513687251 "Schedule of future (projected) sales of the company Repligen Corporation")
Future (projected) sales of companies in the market segment - Dna
Repligen Corporation is a leading supplier of bioprocessing technologies and materials used in the production of biological drugs, such as monoclonal antibodies and gene therapy. The company's growth is driven by advances in biotechnology. This chart shows projected sales for the entire DNA technologies segment, reflecting expected growth in the biopharmaceutical market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513687252 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Repligen Corporation supplies bioprocessing technologies necessary for the production of biological drugs (biopharmaceuticals). Demand for its products is growing alongside the development of the monoclonal antibody and gene therapy markets. This chart reflects the overall economic situation, which influences funding for the biotechnology industry, a key customer for Repligen's products.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513687293 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Repligen Corporation
Repligen supplies bioprocessing technologies used in the production of biological drugs. This metric demonstrates its key role in the pharmaceutical industry. It shows what percentage of the company's revenue from sales of its innovative systems and consumables is converted into net profit, reflecting the high demand for its products.
Market segment marginality - Dna
Repligen develops and supplies materials and technologies used in the production of biological drugs. The company is a "pixes and shovels" supplier to the rapidly growing biopharmaceutical industry. This chart demonstrates its high operational efficiency, reflecting the strong demand for its products and the important role it plays in the production of modern medicines.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Repligen Corporation
Repligen Corporation is a key provider of bioprocessing technologies used in the production of biological drugs. This chart shows how the company is growing alongside the biopharmaceutical industry. The increase in staff is driven by high demand for its filtration and chromatography systems, which are essential for the production of monoclonal antibodies and gene therapy.
Share of the company's employees Repligen Corporation within the market segment - Dna
Repligen Corporation supplies innovative materials and technologies for biopharmaceutical manufacturing. This chart shows the company's concentration of highly qualified bioprocessing specialists. Its team creates products that help produce modern medicines, such as antibodies and vaccines.
Number of employees in the market segment - Dna
Repligen Corporation supplies innovative materials and technologies used in the production of biological drugs (biopharmaceuticals). This chart shows overall employment in the biotechnology sector. Its rapid growth illustrates the explosive development of the antibody, gene, and cell therapy industries, where Repligen's products are critical.
Number of employees in the market as a whole
Repligen supplies bioprocessing technologies used in the production of biological drugs. The growth in personnel in this chart is directly related to the rapid development of the biopharmaceutical industry. The company is expanding production and hiring specialists as its filtration and chromatography systems become critical for the creation of vaccines and antibodies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Repligen Corporation (RGEN)
Repligen supplies bioprocessing technologies for the production of biological drugs. This chart shows that the market highly values its unique and patented products. The company is a critical supplier to the pharmaceutical industry, generating high added value and, consequently, high market capitalization per employee.
%20of%20the%20company%20Repligen%20Corporation%20(RGEN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Repligen-Corporation-RGEN&v=1772513687320 "Chart of market capitalization per employee (in thousands of dollars) of the company Repligen Corporation (RGEN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Repligen is a bioprocessing company. They don't make drugs, but rather produce consumables (filters, proteins) for pharmaceutical companies that do. This is a niche, high-margin operation. This metric, compared to the industry average, reflects how much the market values their unique products per employee.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513687334 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Repligen Corporation supplies bioprocessing technologies used in the production of biological drugs. The company produces critical consumables for the pharmaceutical industry. Its high employee rating reflects its niche leadership, strong patents, and high-margin products, which are integral to the production of high-value drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513687357 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Repligen Corporation (RGEN)
Repligen Corporation supplies bioprocessing technologies used to produce biological drugs (e.g., monoclonal antibodies). Their products include filters and chromatography systems. This chart shows how efficiently their R&D and manufacturing processes produce these critical, high-margin consumables for the pharmaceutical industry.
%20Chart%20Repligen%20Corporation%20(RGEN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Repligen-Corporation-RGEN&v=1772513687369 "Company Profit Per Employee (in thousands of dollars) Chart Repligen Corporation (RGEN)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Repligen (RGEN) is a "supplier" for "biopharmaceuticals." They produce "equipment" and "consumables" for "bioprocessing" (antibody drug production). This chart shows the benchmark for "Dna" (Bioprocessing). This industry has high labor margins. It's a "razor and blades" model: the sector sells "consumables" (blades) for R&D.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513687371 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Repligen (RGEN) is a life sciences company that supplies critical materials and technologies for the production of biological drugs (such as monoclonal antibodies). They also sell filters and proteins. This chart, showing average profit per employee, provides context. It helps understand how profitable the biomanufacturing sector, which relies on scientists and high-tech equipment, is relative to its workforce.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513687387 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Repligen Corporation (RGEN)
This chart for Repligen, a provider of bioprocessing solutions for biologics, reflects the value of its products. Its high revenue per employee demonstrates the critical importance of its filters and reagents to pharmaceutical companies developing and manufacturing advanced drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Repligen-Corporation-RGEN&v=1772513687389 "Sales chart per company employee Repligen Corporation (RGEN)")
Sales per employee in the market segment - Dna
Repligen Corporation supplies bioprocessing technologies used in the production of biological drugs. It is a key supplier to the pharmaceutical industry. This metric measures average revenue per employee by segment. It helps evaluate how productive Repligen's team is in producing and selling biotech consumables and equipment compared to competitors.
Sales per employee for the market as a whole
Repligen (RGEN) supplies critical materials and equipment for biopharmaceutical manufacturing (e.g., protein purification and gene therapy). This metric reflects the demand for their unique consumables from drugmakers. Growing revenue per employee indicates that their products have become industry standards, and R&D is an effective revenue generator.
Short shares by company, segment and market as a whole
Shares shorted by company Repligen Corporation (RGEN)
Repligen supplies consumables (such as filters) for bioprocessing—the production of biological drugs. The company thrived amid the biotech boom, accelerated by the pandemic. This chart reflects investor bets that slowing biotech funding and cuts to R&D budgets will lead to a "hangover" and reduced demand for its products.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Repligen-Corporation-RGEN&v=1772513687414 "Short Shares Chart for the Company Repligen Corporation (RGEN)")
Shares shorted by market segment - Dna
Repligen (RGEN) is a "shovel supplier" for the biotech industry. They produce critical materials (such as proteins) and filtration systems for biopharmaceutical production. This chart shows the overall short position in the biotech sector. It reflects investor concerns about declining R&D funding in biotech, which is reducing demand for consumables.
Shares shorted by the overall market
Repligen (RGEN) supplies bioprocessing equipment (drug production). Their clients are biotech companies. When Short_All rises, it signals risk aversion. This pessimism dries up funding for biotech companies, forcing them to cut R&D and delay production ramp-ups—RGEN's main source of revenue.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Repligen Corporation (RGEN)
Repligen is a biotech "supplier." They sell critical "consumables" (filters, proteins) for the production of biomedicines. **This chart** measures momentum. A funding boom in biotech (RGEN's clients) or news of a breakthrough in gene therapy (which requires their products) can trigger euphoria, pushing **This chart** above 70.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Repligen-Corporation-RGEN&v=1772513687444 "RSI 14 indicator chart for the company's stock Repligen Corporation (RGEN)")
RSI 14 Market Segment - Dna
Repligen Corporation is a "pixes and shovels" supplier to the biopharmaceutical industry. It produces critical materials and equipment (such as filtration) used in the production of biopharmaceuticals. This chart measures the collective momentum of the biotech equipment and DNA research sector. It shows whether RGEN is moving with the overall biotech sector or with its own unique products.
RSI 14 for the overall market
Repligen (RGEN) supplies bioprocessing technologies for the production of biological drugs (e.g., monoclonal antibodies). This business is tied to biotech R&D. This indicator of overall market "risk appetite" is critical for RGEN. During periods of euphoria (high values), biotech companies readily attract funding and spend it on Repligen's equipment. During periods of panic (low values), venture capital dries up.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RGEN (Repligen Corporation)
Repligen (RGEN) is a key provider of bioprocessing technologies. The company produces materials and systems (filters, proteins) needed to manufacture biopharmaceuticals such as monoclonal antibodies and gene therapies. This chart displays the average target price, reflecting analysts' assessments of biopharmaceutical demand and R&D investment by major pharmaceutical companies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RGEN-Repligen-Corporation&v=1772513687529 "A chart showing analyst consensus forecasts for the expected stock price. RGEN (Repligen Corporation)")
The difference between the consensus estimate and the actual stock price RGEN (Repligen Corporation)
Repligen is a supplier to the biotech industry. The company produces critical materials and equipment (such as filters) for the production of biological drugs (biologics). This chart shows the gap between the consensus forecast and the price. It reflects whether analysts believe R&D budgets in the biotech industry will recover.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RGEN-Repligen-Corporation&v=1772513687551 "A chart showing the difference between the consensus forecast and the actual stock price. RGEN (Repligen Corporation)")
Analyst consensus forecast for stock prices by market segment - Dna
Repligen is a "shovel supplier" for biotech. The company produces critical materials (filters, chromatography) for the purification and production of biopharmaceuticals (drugs). This chart shows analysts' overall expectations for the bioprocessing sector. It reflects whether experts believe R&D in the pharmaceutical industry will grow.
Analysts' consensus forecast for the overall market share price
Repligen is the purveyor of the biotech revolution. They produce critical materials (e.g., proteins, filters) for biopharmaceutical production. This chart of overall market sentiment is important. Optimism = easy access to capital for biotech = boom in R&D and drug production = increased orders for Repligen.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Repligen Corporation
Repligen is a supplier to the biotech revolution. They don't create drugs, but rather produce critical consumables (filters, systems) for their production (bioprocessing). This chart is a summary indicator of their blade model. It reflects global R&D spending in biotech and the stable, high-margin demand for their single-use products.
AKIMA Market Segment Index - Dna
Repligen is a supplier of picks and shovels to the biotech industry; the company produces critical consumables (filters, proteins) for bioprocessing—the process used to produce blockbuster drugs. This summary metric evaluates R&D. The graph shows the segment average. This benchmark helps us understand how Repligen's razor-sharp model distinguishes it from the average biotech company.
The AKIM Index for the overall market
Repligen is the pickaxe and shovels of biotech. The company is a leader in bioprocessing, supplying critical materials (filters) for the production of biological drugs. This chart, reflecting the market average, is a backdrop. It helps assess how this defense business, dependent on pharmaceutical R&D budgets, stacks up against the backdrop of overall macroeconomic fluctuations.
